Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 17 studies | 25% ± 12% | |
platelet | 9 studies | 32% ± 9% | |
monocyte | 8 studies | 29% ± 24% | |
non-classical monocyte | 6 studies | 29% ± 12% | |
smooth muscle cell | 6 studies | 29% ± 24% | |
fibroblast | 6 studies | 32% ± 28% | |
conventional dendritic cell | 5 studies | 45% ± 27% | |
macrophage | 5 studies | 38% ± 26% | |
endothelial cell of lymphatic vessel | 5 studies | 36% ± 30% | |
basal cell | 5 studies | 40% ± 28% | |
endothelial cell of vascular tree | 5 studies | 34% ± 30% | |
megakaryocyte | 4 studies | 38% ± 12% | |
myeloid cell | 4 studies | 27% ± 9% | |
epithelial cell | 4 studies | 28% ± 8% | |
endothelial cell | 4 studies | 30% ± 2% | |
ciliated cell | 4 studies | 28% ± 12% | |
dendritic cell | 4 studies | 53% ± 29% | |
pericyte | 4 studies | 38% ± 31% | |
secretory cell | 3 studies | 29% ± 16% | |
leukocyte | 3 studies | 18% ± 3% | |
hematopoietic precursor cell | 3 studies | 33% ± 12% | |
innate lymphoid cell | 3 studies | 44% ± 37% | |
natural killer cell | 3 studies | 46% ± 36% | |
intermediate monocyte | 3 studies | 35% ± 15% | |
gamma-delta T cell | 3 studies | 20% ± 3% | |
mononuclear phagocyte | 3 studies | 21% ± 5% | |
plasmacytoid dendritic cell | 3 studies | 20% ± 2% | |
hematopoietic stem cell | 3 studies | 30% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 2034.99 | 180 / 180 | 100% | 25.58 | 430 / 430 |
uterus | 100% | 2288.49 | 170 / 170 | 100% | 28.92 | 459 / 459 |
esophagus | 100% | 1870.89 | 1444 / 1445 | 100% | 25.94 | 183 / 183 |
thymus | 100% | 1988.29 | 652 / 653 | 100% | 23.26 | 605 / 605 |
stomach | 100% | 1513.15 | 359 / 359 | 100% | 25.32 | 285 / 286 |
intestine | 100% | 2269.79 | 966 / 966 | 100% | 30.33 | 525 / 527 |
kidney | 100% | 2023.63 | 89 / 89 | 100% | 22.62 | 897 / 901 |
breast | 100% | 2039.04 | 459 / 459 | 100% | 35.31 | 1113 / 1118 |
bladder | 100% | 2004.43 | 21 / 21 | 99% | 27.80 | 500 / 504 |
prostate | 100% | 2001.86 | 245 / 245 | 99% | 15.23 | 498 / 502 |
lung | 100% | 3258.84 | 577 / 578 | 99% | 22.31 | 1146 / 1155 |
skin | 100% | 1837.75 | 1809 / 1809 | 99% | 32.54 | 466 / 472 |
adrenal gland | 100% | 1894.62 | 258 / 258 | 99% | 23.62 | 227 / 230 |
brain | 100% | 2051.37 | 2631 / 2642 | 88% | 17.62 | 623 / 705 |
liver | 90% | 647.70 | 204 / 226 | 93% | 10.63 | 376 / 406 |
pancreas | 70% | 457.24 | 231 / 328 | 99% | 28.10 | 176 / 178 |
spleen | 100% | 2887.71 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 26.67 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 29.59 | 1 / 1 |
adipose | 100% | 1867.42 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2791.98 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 7027.51 | 927 / 929 | 0% | 0 | 0 / 0 |
muscle | 99% | 1148.12 | 794 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 14.65 | 28 / 29 |
heart | 97% | 945.97 | 831 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 13.36 | 77 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0031966 | Cellular component | mitochondrial membrane |
GO_0005829 | Cellular component | cytosol |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005634 | Cellular component | nucleus |
GO_0050700 | Molecular function | CARD domain binding |
Gene name | CARD19 |
Protein name | Caspase recruitment domain-containing protein 19 (Bcl10-interacting CARD protein) (BinCARD) |
Synonyms | C9orf89 |
Description | FUNCTION: Plays a role in inhibiting the effects of BCL10-induced activation of NF-kappa-B. May inhibit the phosphorylation of BCL10 in a CARD-dependent manner. . |
Accessions | Q96LW7 ENST00000375464.7 [Q96LW7-2] ENST00000466409.1 [Q96LW7-1] |